Malignancy represents one of the most complex structural and biological anomalies encountered in clinical
medicine, characterized by unregulated cellular proliferation, metabolic hijacking, and a profound capacity to bypass
standard host regulatory mechanisms. This research paper provides an exhaustive, multi-disciplinary evaluation of
oncogenesis, taxonomy, therapeutic paradigms, and upcoming curative frontiers. Through a historical and biochemical
lens, the study analyzes the cellular transition from normal homeostatic tissues to abnormal malignant phenotypes,
contextualizing the microscopic mechanisms of apoptosis evasion, angiogenesis, and systemic metastasis. A critical
evaluation is made of current therapeutic models, directly contrasting the curative mechanics of modern Allopathic
oncology with the supportive and palliative limitations of traditional systems like Ayurveda and Homeopathy.
Furthermore, this study details the systemic signs of malignancy, validating the clinical 'Rule of Persistence' as a core
investigative parameter. Finally, it explores next-generation interventions—including mRNA neoantigen vaccines,
targeted proteasomal degraders (PROTACs), Targeted Alpha Therapy radiopharmaceuticals, and AI-driven early liquid
biopsies—charting the clinical evolution from treating advanced terminal conditions to executing precise molecular
interventions.